Compare Heron Therapeutics Inc (HRTX) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Noble Corporation plc — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while Noble Corporation plc trades at $44.25 (market cap $6.51B). The key difference: Noble Corporation plc is far larger — about 102.7× Heron Therapeutics Inc's market cap, and Noble Corporation plc pays a 4.91% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | NE | |
|---|---|---|
Market Cap | $63.41M | $6.51B |
Sector | Health | Technology |
52-Week High | $1.49 | $54.37 |
52-Week Low | $0.32 | $26.61 |
Enterprise Value | $161.31M | $7.94B |
Dividend Yield | — | 4.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Noble Corporation (NE) trades at $40.77, up 0.2% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported Q2 2026 earnings of $0.01 per share, missing estimates, while revenue declined to $3.1B in 2026 from $3.3B in 2025. Recent news includes a fraud investigation announcement and new drilling contracts, creating investor uncertainty amid operational challenges.
The outlook remains cautious with analyst consensus at Buy (31%) and a $46 price target offering 13% upside. Key risks include earnings volatility, legal scrutiny, and competitive pressures in offshore drilling. Positive cash flow and dividend payments provide some stability, but execution on new contracts and margin improvement are critical for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
